The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Incubator/Accelerator | Alive

About VoxNeuro

VoxNeuro’s Cognitive Health Assessment provides insight into brain function through quantitative, objective data. It differentiates between true cognitive decline and perceived decline due to symptoms caused by situational factors, such as stress, general fatigue, or mood.

VoxNeuro Headquarter Location

McMaster Innovation Park Suite 305 – 175 Longwood Rd S

Hamilton, Ontario, L8P 0A1,



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing VoxNeuro

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

VoxNeuro is included in 2 Expert Collections, including Medical Devices.


Medical Devices

7,913 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

Latest VoxNeuro News

VoxNeuro Awarded Patent, Appoints New CEO

May 12, 2022

Jason Flowerday assumes the company's reigns as it establishes a clinical study program to help expand its product offerings. Jason Flowerday. Michael Barbella, Managing Editor05.12.22 It's been a year of milestones so far for  VoxNeuro Inc. Besides obtaining a patent (11278230, titled “Systems and methods for cognitive health assessment”) that protects its proprietary technology, VoxNeuro has appointed Jason Flowerday as CEO. Flowerday assumes leadership of the firm as it establishes a U.S.-based expert clinical study program to help expand VoxNeuro's product offerings in various neurological pathologies. Since its inception, VoxNeuro has been led by co-founder James Connolly, son of John F. Connolly, Ph.D., the world-renowned neuroscientist responsible for the company’s cognitive assessment technology. With Flowerday as CEO, James Connolly will assume the new role of chief business officer, overseeing the organization’s key initiatives in the U.S. market. “Jason's entrepreneurial drive and commitment to being a champion for change, and the incredible amount of commercial success that he brings with him to VoxNeuro as its new chief executive officer, is a critical step forward on our mission to become The Brain Company.” said Connolly. Flowerday brings more than 25 years of industry-relevant, executive leadership experience to VoxNeuro. His success in the life sciences and health technology sectors began with Bayer and Johnson & Johnson, followed by CEO roles across specialty pharmaceutical, medical device, diagnostics, and health tech companies. During his time leading these companies, Flowerday was successful in the pursuit of new markets, investment capital, revenue growth and multiple liquidity events. From 2018 to 2021, Flowerday was CEO for MDBriefCase, a global health tech company providing digital medical education to physicians, pharmacists and nurses. Through his stewardship, MDBriefCase was acquired by Think Research, a developer of knowledge-based digital healthcare solutions. “I am excited to join VoxNeuro at this critical time in the organization’s growth. The team that James Connolly has assembled and the suite of SaMD products that are being built have all of the makings to change how brain health is understood on a global scale, resulting in the marked improvement of human lives. The company’s progress with its current product for general cognitive health assessment, plus significant advances with its intellectual property and its U.S. clinical program strategy, were the catalysts that convinced me that it was on a path to success in a nascent market ready for disruption.” said Flowerday. Flowerday joins VoxNeuro as it prepares to solidify its product development plans and pipeline. After launching its first product last spring, a Software as a Medical Device (SaMD) general cognitive assessment that healthcare providers leverage in clinical decision-making, VoxNeuro is formalizing partnerships with channel partners to assist with its roll-out across the United States. In parallel, the company is working to finalize its initial clinical programs with leading American institutions and medical specialists to develop a series of diagnostic products for depression, concussion, Alzheimer’s, schizophrenia and bi-polar disorder. The company expects that these clinical programs will begin in the second half of 2022. VoxNeuro is an SaMD brain health company that developed technology for analyzing brain-based biomarkers to assess cognitive function. It delivers a comprehensive understanding of how a brain is functioning by measuring attention and concentration, information processing, and working memory. The company’s technology is based on thorough research, with more than 300 peer-reviewed publications on EEG, including numerous breakthrough findings, published by Chief Science Officer John F. Connolly since 1982. The company’s competitive advantage involves EEG-based neuropsychological assessments that generate event-related potentials associated with key cognitive functions, and the output of a cognitive health report. VoxNeuro is headquartered at McMaster Innovation Park in Hamilton, Ontario, Canada. Related Content

VoxNeuro Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

VoxNeuro Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.